Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The anti-rheumatoid drug D-penicillamine (D-pen) has a reactive sulfhydryl group capable of modifying self antigens, and can provoke typical autoantibody-mediated myasthenia gravis (MG), especially in DR1+ individuals. We have selected T cell clones from one such patient that were highly specific for D-pen but not its L-isomer or D-cysteine. Moreover, they were restricted to HLA-DR1, had a Th1 phenotype and used TCR V alpha4.1, V beta6.1. They responded well to blood mononuclear cells prepulsed with D-pen either in the absence of serum or after chloroquine treatment, but not to autologous D-pen-pulsed B cell lines. Thus, D-pen may directly couple to distinctive peptides resident in surface DR1 molecules on circulating macrophages or dendritic cells.

Type

Journal article

Journal

J Neuroimmunol

Publication Date

01/06/1999

Volume

97

Pages

146 - 153

Keywords

Aged, Amino Acid Sequence, Antigens, CD3, Antirheumatic Agents, Autoimmune Diseases, Base Sequence, Blood Proteins, CD4-Positive T-Lymphocytes, Cell Line, Chloroquine, Drug Hypersensitivity, Epitopes, Female, HLA-DR1 Antigen, Histocompatibility Antigens Class II, Humans, Molecular Sequence Data, Myasthenia Gravis, Penicillamine, Protein Binding, Receptors, Antigen, T-Cell, alpha-beta, Thymidine, Tritium